

## Supplementary Documents [IFRS]

Financial results for the first nine months of the fiscal year 2023 (FY2023)

### Astellas Pharma Inc.

- Q3/FY2023 Financial Results
  - Nine months ended December 31, 2023
  - Three months ended December 31, 2023
- Pipeline list

#### Cautionary Notes

*In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.*

## [Nine months ended December 31, 2023]

### 1. Consolidated Results (Full Basis)

Unit: B¥

	FY22 APR. - DEC.	FY23 APR. - DEC.	Change	Change (%)	FY22 Full Year	Previous Forecast FY23 Full Year	Latest Forecast FY23 Full Year	Change from FY22
Revenue	1,164.4	1,189.1	24.7	2.1%	1,518.6	1,608.0	1,562.0	2.9%
Cost of sales	226.1	219.3	-6.8	-3.0%	288.4			
Ratio to Revenue	19.4%	18.4%			19.0%			
Gross profit	938.3	969.8	31.5	3.4%	1,230.3			
SG&A expenses	471.0	547.0	76.0	16.1%	630.3	737.0	731.0	16.0%
Ratio to Revenue	40.4%	46.0%			41.5%	45.8%	46.8%	
XTANDI co-promotion fee in the United States	138.2	146.2	8.0	5.8%	175.5	187.0	187.0	6.6%
Personnel expenses	156.3	177.8	21.5	13.7%	211.4			
Advertising and Sales Promotion and Other	176.5	222.9	46.5	26.3%	243.4			
R&D expenses	206.1	216.3	10.3	5.0%	276.1	290.0	286.0	3.6%
Ratio to Revenue	17.7%	18.2%			18.2%	18.0%	18.3%	
Amortisation of intangible assets	29.2	66.2	37.0	126.8%	38.4			
Gain on divestiture of intangible assets	0.2	9.7	9.5	-	0.2			
Share of profit (loss) of investments accounted for using equity method	1.4	-0.5	-1.8	-	1.3			
Other income	2.5	8.5	6.0	236.6%	3.6			
Fair value remeasurements on contingent consideration	1.5	2.6	1.1	73.0%	2.3			
Other expenses	54.9	84.0	29.1	52.9%	157.5			
Impairment losses	24.3	13.8	-10.5	-43.4%	84.6			
Restructuring costs	1.5	18.4	16.9	-	4.5			
Fair value remeasurements on contingent consideration	19.0	16.7	-2.3	-11.9%	53.1			
Replacement awards with business combination*	-	33.1	33.1	-	-			
Operating profit	181.3	74.1	-107.2	-59.1%	133.0	123.0	83.0	-37.6%
Ratio to Revenue	15.6%	6.2%			8.8%	7.6%	5.3%	
Finance income	5.7	7.3	1.7	29.4%	8.1			
Finance expenses	6.7	7.8	1.1	16.6%	8.8			
Profit before tax	180.2	73.6	-106.6	-59.1%	132.4	121.0	82.0	-38.0%
Ratio to Revenue	15.5%	6.2%			8.7%	7.5%	5.2%	
Income tax expense	35.4	23.3	-12.1	-34.2%	33.6			
Profit	144.8	50.3	-94.5	-65.3%	98.7	85.0	58.0	-41.2%
Ratio to Revenue	12.4%	4.2%			6.5%	5.3%	3.7%	
Comprehensive income	218.6	113.9	-104.6	-47.9%	205.3			

(\*) Payment for Iveric Bio's unvested share-based payments, such as share options

## 2. Consolidated Results (Core Basis)

Unit: B¥

	FY22 APR. - DEC.	FY23 APR. - DEC.	Change	Change (%)
Revenue	1,164.4	1,189.1	24.7	2.1%
Cost of sales	226.1	219.3	-6.8	-3.0%
Ratio to Revenue	19.4%	18.4%		
Gross profit	938.3	969.8	31.5	3.4%
SG&A expenses	471.0	547.0	76.0	16.1%
Ratio to Revenue	40.4%	46.0%		
XTANDI co-promotion fee in the United States	138.2	146.2	8.0	5.8%
Personnel expenses	156.3	177.8	21.5	13.7%
Advertising and Sales Promotion and Other	176.5	222.9	46.5	26.3%
R&D expenses	206.1	216.3	10.3	5.0%
Ratio to Revenue	17.7%	18.2%		
Amortisation of intangible assets	29.2	66.2	37.0	126.8%
Gain on divestiture of intangible assets	0.2	9.7	9.5	-
Share of profit (loss) of investments accounted for using equity method	1.4	-0.5	-1.8	-
Operating profit	233.7	149.6	-84.0	-36.0%
Ratio to Revenue	20.1%	12.6%		
Finance income	5.7	7.3	1.7	29.4%
Finance expenses	6.7	7.8	1.1	16.6%
Profit before tax	232.6	149.1	-83.5	-35.9%
Ratio to Revenue	20.0%	12.5%		
Income tax expense	43.7	28.6	-15.1	-34.5%
Profit	188.9	120.5	-68.4	-36.2%
Ratio to Revenue	16.2%	10.1%		

	Previous Forecast	Latest Forecast	Change from FY22
FY22 Full Year			
FY23 Full Year	1,608.0	1,562.0	2.9%
Ratio to Revenue			
FY22 Full Year			
FY23 Full Year	737.0	731.0	16.0%
Ratio to Revenue	45.8%	46.8%	
XTANDI co-promotion fee in the United States	187.0	187.0	6.6%
Personnel expenses			
Advertising and Sales Promotion and Other			
R&D expenses	290.0	286.0	3.6%
Ratio to Revenue	18.0%	18.3%	
Amortisation of intangible assets			
Gain on divestiture of intangible assets			
Share of profit (loss) of investments accounted for using equity method			
Operating profit	199.0	164.0	-42.8%
Ratio to Revenue	12.4%	10.5%	
Finance income			
Finance expenses			
Profit before tax			
Ratio to Revenue			
Income tax expense			
Profit	154.0	127.0	-43.5%
Ratio to Revenue	9.6%	8.1%	

## 3. Exchange Rate

Unit: yen

	FY22 APR. - DEC.Ave.	FY23 APR. - DEC.Ave.	FY22 End	FY23 Q3 End
USD/Yen	137	143	133	141
EUR/Yen	141	155	144	156

	Previous Forecast	Latest Forecast
FY22 Full Year		
FY23 Full Year	140	140
FY23 Full Year	152	152

\* Fx impacts: Revenue +58.8 billion yen and Core operating profit +13.8 billion yen

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

	FY22 APR. - DEC.			FY23 APR. - DEC.		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
<b>Revenue</b>	<b>1,164.4</b>	-	<b>1,164.4</b>	<b>1,189.1</b>	-	<b>1,189.1</b>
Cost of sales	226.1	-	226.1	219.3	-	219.3
<b>Gross profit</b>	<b>938.3</b>	-	<b>938.3</b>	<b>969.8</b>	-	<b>969.8</b>
SG&A expenses	471.0	-	471.0	547.0	-	547.0
R&D expenses	206.1	-	206.1	216.3	-	216.3
Amortisation of intangible assets	29.2	-	29.2	66.2	-	66.2
Gain on divestiture of intangible assets	0.2	-	0.2	9.7	-	9.7
Share of profit (loss) of investments accounted for using equity method	1.4	-	1.4	-0.5	-	-0.5
Other income *	2.5	-2.5	-	8.5	-8.5	-
Other expenses *	54.9	-54.9	-	84.0	-84.0	-
<b>Operating profit</b>	<b>181.3</b>	<b>52.4</b>	<b>233.7</b>	<b>74.1</b>	<b>75.5</b>	<b>149.6</b>
Finance income	5.7	-	5.7	7.3	-	7.3
Finance expenses	6.7	-	6.7	7.8	-	7.8
<b>Profit before tax</b>	<b>180.2</b>	<b>52.4</b>	<b>232.6</b>	<b>73.6</b>	<b>75.5</b>	<b>149.1</b>
Income tax expense	35.4	8.3	43.7	23.3	5.3	28.6
<b>Profit</b>	<b>144.8</b>	<b>44.1</b>	<b>188.9</b>	<b>50.3</b>	<b>70.2</b>	<b>120.5</b>

\* "Other income" and "Other expenses" are excluded from Core basis results.

"Other income" and "Other expenses" include gain/loss on sale and disposal of property, plant and equipment, impairment losses, restructuring costs, litigation costs and foreign exchange gains/losses, etc.

## 5. Revenue by Region

Unit: B¥

		FY22 APR. - DEC.	FY23 APR. - DEC.	Change	Change (%)
Revenue		1,164.4	1,189.1	24.7	2.1%
	Japan	204.5	211.0	6.5	3.2%
	Ratio to Revenue	17.6%	17.7%		
	United States	501.1	481.4	-19.7	-3.9%
	Ratio to Revenue	43.0%	40.5%		
	Established Markets	272.2	306.3	34.1	12.5%
	Ratio to Revenue	23.4%	25.8%		
	Greater China	65.2	67.3	2.2	3.3%
	Ratio to Revenue	5.6%	5.7%		
	International Markets	104.2	118.8	14.6	14.0%
	Ratio to Revenue	8.9%	10.0%		
	Others	17.2	4.2	-13.0	-75.7%
	Ratio to Revenue	1.5%	0.4%		

FY22 Full Year	Previous Forecast	Latest Forecast	Change from FY22
	FY23 Full Year	FY23 Full Year	Change (%)
1,518.6	1,608.0	1,562.0	2.9%
262.3	278.4	278.4	6.1%
17.3%	17.3%	17.8%	
652.4	691.0	645.5	-1.1%
43.0%	43.0%	41.3%	
359.8	398.4	397.9	10.6%
23.7%	24.8%	25.5%	
80.0	85.1	85.1	6.3%
5.3%	5.3%	5.4%	
143.3	150.0	149.8	4.5%
9.4%	9.3%	9.6%	
20.7	5.2	5.3	-74.2%
1.4%	0.3%	0.3%	

- Established Markets: Europe, Canada, etc.

- Greater China: China, Hong Kong, Taiwan

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Australia, Export sales, etc.

- From FY2023 Q1, the commercial segment of some countries were changed from International Markets to Established Markets. All figures above reflect this change

## 6. Investment in Property, Plant and Equipment

### Depreciation/Amortisation

Unit: B¥

	FY22 APR. - DEC.	FY23 APR. - DEC.	Change	Change (%)
Investment in Property, Plant and Equipment	24.6	22.9	-1.7	-7.0%
Depreciation (PP&E)	29.8	30.7	0.9	3.1%
Amortisation of Intangible Assets (incl. software, etc.)	52.9	78.5	25.6	48.3%

FY22 Full Year	Latest Forecast	Change from FY22
	FY23 Full Year	Change (%)
36.6	39.0	6.7%
40.0	43.0	7.4%
65.7	112.0	70.4%

- Investment in Property, Plant and Equipment does not include right-of-use asset

7. Sales of major products

1) Global

Unit: B¥

	Unit: B¥				FY22 Full Year	Change from FY22	
	FY22 APR. - DEC.	FY23 APR. - DEC.	Change	Change (%)		Latest Forecast FY23 Full Year	Change (%)
XTANDI	511.9	560.0	48.1	9.4%	661.1	719.8	8.9%
Japan	42.3	44.1	1.8	4.3%	54.7	58.2	6.3%
United States	269.2	284.9	15.8	5.9%	341.8	363.8	6.4%
Established Markets	150.0	171.4	21.4	14.3%	197.9	221.8	12.1%
Greater China	9.8	13.5	3.7	37.3%	11.1	16.1	45.4%
International Markets	40.6	46.1	5.5	13.5%	55.6	60.0	7.8%
PADCEV	33.1	55.6	22.5	68.1%	44.4	85.2	91.6%
Japan	6.3	6.5	0.2	3.2%	8.4	9.9	18.2%
United States	22.0	39.0	17.0	77.3%	29.2	60.2	106.4%
Established Markets	4.7	9.4	4.7	99.9%	6.8	14.0	106.6%
Greater China	-	0.2	0.2	-	-	0.2	-
International Markets	0.1	0.5	0.4	602.4%	0.1	0.8	775.4%
XOSPATA	36.3	41.3	5.0	13.8%	46.6	55.2	18.6%
Japan	3.4	3.4	0.0	0.8%	4.3	4.6	6.3%
United States	20.1	21.1	1.0	5.1%	25.5	29.5	15.4%
Established Markets	8.8	11.2	2.4	27.3%	12.1	14.5	20.2%
Greater China	2.4	2.9	0.5	20.0%	2.5	2.9	17.4%
International Markets	1.6	2.7	1.1	67.8%	2.2	3.8	71.3%
VEOZAH	-	3.6	3.6	-	-	7.1*	-
United States	-	3.6	3.6	-	-	7.1	-
IZERVAY	-	5.3	5.3	-	-	11.0	-
United States	-	5.3	5.3	-	-	11.0	-
EVRENZO	2.4	3.3	0.9	36.4%	3.2	5.1	57.8%
Japan	1.9	1.7	-0.2	-12.3%	2.4	2.2	-8.2%
Established Markets	0.4	1.3	0.9	209.1%	0.6	2.0	212.3%
International Markets	0.1	0.3	0.2	325.4%	0.2	0.9	435.1%
BETANIS/MYRBETRIQ/BETMIGA	141.0	142.9	1.8	1.3%	188.6	194.4	3.1%
Japan	26.4	21.4	-5.0	-18.8%	33.5	29.0	-13.5%
United States	70.4	70.3	-0.1	-0.1%	96.5	99.3	3.0%
Established Markets	32.3	37.4	5.1	15.8%	42.9	49.2	14.8%
Greater China	3.1	2.8	-0.2	-7.3%	3.9	3.6	-9.0%
International Markets	8.9	10.8	2.0	22.1%	11.8	13.3	12.7%
PROGRAF	151.6	155.4	3.7	2.5%	198.8	196.5	-1.1%
Japan	28.1	23.5	-4.6	-16.3%	35.6	29.8	-16.2%
United States	8.2	7.6	-0.6	-7.0%	10.7	10.3	-3.8%
Established Markets	53.3	55.1	1.8	3.3%	69.8	70.7	1.3%
Greater China	37.2	36.8	-0.5	-1.2%	46.8	48.0	2.6%
International Markets	24.8	32.3	7.5	30.4%	35.8	37.6	5.0%
VESICARE	12.4	11.4	-0.9	-7.6%	15.9	13.9	-12.7%

- FY2022 sales of products in Japan are shown in a gross sales basis. FY2023 sales and forecasts are shown in a net sales basis, as in other regions

- Established Markets: Europe, Canada, etc.

- Greater China: China, Hong Kong, Taiwan

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Australia, Export sales, etc.

- From FY2023 Q1, the commercial segment of some countries were changed from International Markets to Established Markets. All figures above reflect this change

- PADCEV (United States): Co-promotion revenue from Pfizer

- Astellas' EVRENZO territories: Japan, Europe, the Commonwealth of Independent States, Middle East, South Africa, etc.

\* Only VEOZAH's forecast was revised from ¥53.3B disclosed in Nov 2023

2) Revenue by region - FY2022 sales of products in Japan are shown in a gross sales basis. FY2023 sales and forecasts are shown in a net sales basis, as in other regions.

(1) Japan

<Global>	Unit: B¥				FY22 Full Year	Change from FY22	
	FY22 APR. - DEC.	FY23 APR. - DEC.	Change	Change (%)		Latest Forecast FY23 Full Year	Change (%)
XTANDI	42.3	44.1	1.8	4.3%	54.7	58.2	6.3%
PADCEV	6.3	6.5	0.2	3.2%	8.4	9.9	18.2%
XOSPATA	3.4	3.4	0.0	0.8%	4.3	4.6	6.3%
EVRENZO	1.9	1.7	-0.2	-12.3%	2.4	2.2	-8.2%
BETANIS	26.4	21.4	-5.0	-18.8%	33.5	29.0	-13.5%
PROGRAF (Including GRACEPTOR)	28.1	23.5	-4.6	-16.3%	35.6	29.8	-16.2%
HARNAL	1.4	1.1	-0.4	-25.0%	1.8	1.4	-24.2%
<b>&lt;Main products&gt;</b>							
SUGLAT [Family]	23.7	21.9	-1.8	-7.5%	30.3	29.1	-3.9%
SUJANU	9.7	8.7	-1.0	-10.3%	12.3		
REPATHA	4.9	5.2	0.3	5.5%	6.4		
LINZESS	5.5	5.0	-0.5	-8.3%	7.0	7.2	2.5%
BLINCYTO	6.0	8.3	2.3	37.7%	7.9		
EVENITY	31.5	36.7	5.2	16.7%	42.1		
SMYRAF	1.9	1.9	-0.0	-1.1%	2.5	2.7	10.8%
Vaccines	5.8	4.4	-1.4	-24.0%	5.5	5.1	-6.9%
CIMZIA	8.8	7.8	-1.0	-11.3%	11.2		
Total Rx Sales In Japanese market	202.8	210.2	7.5	3.7%	260.1	277.3	6.6%

(2) United States

Revenue	Unit: M\$				FY22 Full Year	Change from FY22	
	FY22 APR. - DEC.	FY23 APR. - DEC.	Change	Change (%)		Latest Forecast FY23 Full Year	Change (%)
	3,671	3,361	-310	-8.4%	4,816	4,594	-4.6%
XTANDI	1,972	1,989	17	0.9%	2,523	2,589	2.6%
PADCEV	161	272	111	69.0%	215	428	99.0%
XOSPATA	147	147	0	0.2%	188	210	11.3%
VEOZAH	-	25	25	-	-	50*	-
IZERVAY	-	37	37	-	-	79	-
MYRBETRIQ	516	491	-25	-4.8%	712	707	-0.7%
PROGRAF	60	53	-7	-11.3%	79	74	-7.2%
AMBISOME	86	84	-2	-2.7%	118	100	-15.2%
CRESEMBA	161	194	34	20.9%	228	272	19.3%
LEXISCAN	546	58	-488	-89.3%	725	75	-89.6%

\* Only VEOZAH's forecast was revised from \$375M disclosed in Apr 2023

(3) Established Markets

Unit: M€

	FY22 APR. - DEC.	FY23 APR. - DEC.	Change	Change (%)
Revenue	1,937	1,973	36	1.9%
XTANDI	1,067	1,104	36	3.4%
PADCEV	33	60	27	81.0%
XOSPATA	63	72	9	15.2%
EVRENZO	3	9	6	179.8%
BETMIGA	230	241	11	4.8%
PROGRAF	379	355	-25	-6.5%
OMNIC	52	51	-1	-2.8%

FY22 Full Year
2,554
1,405
48
86
4
304
495
69

Latest Forecast FY23 Full Year	Change from FY22 (%)
2,623	2.7%
1,462	4.1%
93	91.9%
96	11.6%
13	190.1%
324	6.7%
466	-5.9%
65	-5.2%

- Established Markets: Europe, Canada, etc.

- From FY2023 Q1, the commercial segment of some countries were changed from International Markets to Established Markets. All figures above reflect this change

(4) Greater China

Unit: B¥

	FY22 APR. - DEC.	FY23 APR. - DEC.	Change	Change (%)
Revenue	65.2	67.3	2.2	3.3%
XTANDI	9.8	13.5	3.7	37.3%
PADCEV	-	0.2	0.2	-
XOSPATA	2.4	2.9	0.5	20.0%
BETMIGA	3.1	2.8	-0.2	-7.3%
PROGRAF	37.2	36.8	-0.5	-1.2%
HARNAL	6.7	6.4	-0.4	-5.2%
FEBURIC	2.6	2.7	0.1	4.3%

FY22 Full Year
80.0
11.1
-
2.5
3.9
46.8
8.2
3.4

Latest Forecast FY23 Full Year	Change from FY22 (%)
85.1	6.3%
16.1	45.4%
0.2	-
2.9	17.4%
3.6	-9.0%
48.0	2.6%
8.7	6.4%
3.3	-2.2%

- Greater China: China, Hong Kong, Taiwan

(5) International Markets

Unit: B¥

	FY22 APR. - DEC.	FY23 APR. - DEC.	Change	Change (%)
Revenue	104.2	118.8	14.6	14.0%
XTANDI	40.6	46.1	5.5	13.5%
PADCEV	0.1	0.5	0.4	602.4%
XOSPATA	1.6	2.7	1.1	67.8%
EVRENZO	0.1	0.3	0.2	325.4%
BETMIGA	8.9	10.8	2.0	22.1%
PROGRAF	24.8	32.3	7.5	30.4%
HARNAL	13.5	13.7	0.2	1.7%

FY22 Full Year
143.3
55.6
0.1
2.2
0.2
11.8
35.8
17.9

Latest Forecast FY23 Full Year	Change from FY22 (%)
149.8	4.5%
60.0	7.8%
0.8	775.4%
3.8	71.3%
0.9	435.1%
13.3	12.7%
37.6	5.0%
18.7	4.2%

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Australia, Export sales, etc.

- From FY2023 Q1, the commercial segment of some countries were changed from International Markets to Established Markets. All figures above reflect this change



## 8. Consolidated statements of financial position

Unit: B¥

	FY22 End	FY23 Q3 End	Change
<b>Assets</b>	<b>2,456.5</b>	<b>3,368.7</b>	<b>912.2</b>
<b>Non-current assets</b>	<b>1,406.6</b>	<b>2,318.6</b>	<b>912.0</b>
Property, plant and equipment	286.5	289.0	2.6
Goodwill	328.4	388.0	59.6
Intangible assets	562.5	1,452.3	889.8
Trade and other receivables	24.2	20.8	-3.4
Investments accounted for using equity method	12.7	15.6	2.9
Deferred tax assets	84.2	42.6	-41.5
Other financial assets	97.9	101.6	3.7
Other non-current assets	10.3	8.6	-1.7
<b>Current assets</b>	<b>1,050.0</b>	<b>1,050.1</b>	<b>0.1</b>
Inventories	174.4	226.0	51.6
Trade and other receivables	428.0	496.0	68.0
Income tax receivable	17.8	9.9	-7.9
Other financial assets	19.8	31.5	11.7
Other current assets	32.4	31.6	-0.8
Cash and cash equivalents	376.8	254.0	-122.9
Assets held for sale	0.7	1.2	0.4

Unit: B¥

	FY22 End	FY23 Q3 End	Change
<b>Equity and Liabilities</b>	<b>2,456.5</b>	<b>3,368.7</b>	<b>912.2</b>
<b>Equity</b>	<b>1,508.0</b>	<b>1,503.3</b>	<b>-4.7</b>
<b>Equity attributable to owners of the parent</b>	<b>1,508.0</b>	<b>1,503.3</b>	<b>-4.7</b>
Share capital	103.0	103.0	-
Capital surplus	181.3	183.0	1.7
Treasury shares	-25.1	-34.1	-9.0
Retained earnings	908.2	838.6	-69.5
Other components of equity	340.6	412.8	72.2
<b>Liabilities</b>	<b>948.6</b>	<b>1,865.4</b>	<b>916.9</b>
<b>Non-current liabilities</b>	<b>222.5</b>	<b>711.7</b>	<b>489.2</b>
Bonds and borrowings	50.0	463.8	413.8
Trade and other payables	4.2	2.2	-2.1
Deferred tax liabilities	6.0	70.0	64.0
Retirement benefit liabilities	24.8	26.5	1.7
Provisions	6.5	5.4	-1.1
Other financial liabilities	89.9	99.7	9.7
Other non-current liabilities	41.0	44.1	3.2
<b>Current liabilities</b>	<b>726.0</b>	<b>1,153.7</b>	<b>427.7</b>
Bonds and borrowings	75.0	407.2	332.2
Trade and other payables	140.2	150.4	10.2
Income tax payable	5.1	34.8	29.7
Provisions	17.9	13.8	-4.0
Other financial liabilities	105.1	100.6	-4.5
Other current liabilities	382.7	446.8	64.1

## [Three months ended December 31, 2023]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY23					
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Revenue	375.0	-1.8%	392.1	3.1%	421.9	4.9%
Cost of sales	68.9	-22.4%	74.4	18.5%	75.9	2.0%
Ratio to Revenue	18.4%		19.0%		18.0%	
Gross profit	306.0	4.5%	317.7	0.0%	346.0	5.6%
SG&A expenses	168.2	9.6%	179.3	16.0%	199.5	22.4%
Ratio to Revenue	44.8%		45.7%		47.3%	
XTANDI co-promotion fee in the United States	44.6	3.4%	48.5	4.2%	53.2	9.5%
Personnel expenses	57.4	12.0%	58.9	9.9%	61.6	19.5%
Advertising and Sales Promotion and Other	66.3	12.2%	71.9	32.1%	84.7	34.6%
R&D expenses	64.6	-12.7%	77.4	18.7%	74.4	11.2%
Ratio to Revenue	17.2%		19.7%		17.6%	
Amortisation of intangible assets	9.1	-15.6%	24.7	167.4%	32.4	252.4%
Gain on divestiture of intangible assets	0.1	-68.5%	9.4	-	0.3	791.2%
Share of profit (loss) of investments accounted for using equity method	0.7	96.2%	-0.9	-	-0.2	-
Other income	3.9	-76.0%	3.3	-	2.6	136.8%
Fair value remeasurements on contingent consideration	2.6	80.0%	0.1	-28.3%	0.5	-48.2%
Other expenses	23.1	-40.0%	38.8	989.9%	23.4	-16.3%
Impairment losses	10.5	-52.2%	2.7	263.4%	0.6	-63.0%
Restructuring costs	1.4	-	1.4	29.8%	15.6	-
Fair value remeasurements on contingent consideration	10.1	-35.8%	1.3	-	5.9	45.3%
Replacement awards with business combination*	-	-	32.6*	-	0.5	-
Operating profit	45.8	38.2%	9.4	-89.2%	19.0	-69.1%
Ratio to Revenue	12.2%		2.4%		4.5%	
Finance income	3.8	307.2%	2.4	-33.4%	1.2	0.6%
Finance expenses	2.7	13.5%	2.3	50.5%	2.8	1.0%
Profit before tax	46.8	47.9%	9.5	-89.3%	17.3	-71.0%
Ratio to Revenue	12.5%		2.4%		4.1%	
Income tax expense	13.7	99.8%	6.8	-60.5%	2.8	-75.3%
Profit	33.1	33.5%	2.7	-96.3%	14.5	-70.0%
Ratio to Revenue	8.8%		0.7%		3.4%	
Comprehensive income	134.5	0.1%	57.9	-47.0%	-78.7	-213.0%

(\*) Payment for Iveric Bio's unvested share-based payments, such as share options

(\*\*) In the third quarter, further facts came to light and additional analysis was performed. As a result, "Replacement awards with business combination" was adjusted retroactively.

## 2. Consolidated Results (Core Basis)

Unit: B¥

	FY23					
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Revenue	375.0	-1.8%	392.1	3.1%	421.9	4.9%
Cost of sales	68.9	-22.4%	74.4	18.5%	75.9	2.0%
Ratio to Revenue	18.4%		19.0%		18.0%	
Gross profit	306.0	4.5%	317.7	0.0%	346.0	5.6%
SG&A expenses	168.2	9.6%	179.3	16.0%	199.5	22.4%
Ratio to Revenue	44.8%		45.7%		47.3%	
XTANDI co-promotion fee in the United States	44.6	3.4%	48.5	4.2%	53.2	9.5%
Personnel expenses	57.4	12.0%	58.9	9.9%	61.6	19.5%
Advertising and Sales Promotion and Other	66.3	12.2%	71.9	32.1%	84.7	34.6%
R&D expenses	64.6	-12.7%	77.4	18.7%	74.4	11.2%
Ratio to Revenue	17.2%		19.7%		17.6%	
Amortisation of intangible assets	9.1	-15.6%	24.7	167.4%	32.4	252.4%
Gain on divestiture of intangible assets	0.1	-68.5%	9.4	-	0.3	791.2%
Share of profit (loss) of investments accounted for using equity method	0.7	96.2%	-0.9	-	-0.2	-
Operating profit	64.9	17.4%	44.9	-50.2%	39.8	-54.9%
Ratio to Revenue	17.3%		11.4%		9.4%	
Finance income	3.8	307.2%	2.4	-33.4%	1.2	0.6%
Finance expenses	2.7	13.5%	2.3	50.5%	2.8	1.0%
Profit before Tax	66.0	22.6%	45.0	-51.2%	38.2	-56.0%
Ratio to Revenue	17.6%		11.5%		9.0%	
Income tax expense	14.2	77.7%	7.0	-61.0%	7.4	-58.1%
Profit	51.8	13.0%	38.0	-48.8%	30.7	-55.4%
Ratio to Revenue	13.8%		9.7%		7.3%	

### 3. Revenue by Region

Unit: B¥

		FY23					
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Revenue		375.0	-1.8%	392.1	3.1%	421.9	4.9%
	Japan	68.3	2.2%	69.3	4.2%	73.5	3.1%
	Ratio to Revenue	18.2%		17.7%		17.4%	
	United States	150.0	-6.8%	156.7	-6.4%	174.7	1.1%
	Ratio to Revenue	40.0%		40.0%		41.4%	
	Established Markets	96.8	11.8%	102.3	15.0%	107.2	10.9%
	Ratio to Revenue	25.8%		26.1%		25.4%	
	Greater China	22.5	-2.7%	22.4	2.3%	22.4	11.4%
	Ratio to Revenue	6.0%		5.7%		5.3%	
	International Markets	34.7	2.4%	39.9	17.5%	44.2	21.6%
	Ratio to Revenue	9.3%		10.2%		10.5%	
	Others	2.6	-75.1%	1.6	-8.0%	0.0	-99.5%
	Ratio to Revenue	0.7%		0.4%		0.0%	

- Established Markets: Europe, Canada, etc.

- Greater China: China, Hong Kong, Taiwan

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Australia, Export sales, etc.

- From FY2023 Q1, the commercial segment of some countries were changed from International Markets to Established Markets. All figures above reflect this change

### 4. Depreciation/Amortisation

Unit: B¥

		FY23					
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Investment in Property, Plant and Equipment		9.3	-20.1%	7.4	27.1%	6.1	-13.4%
Depreciation (PP&E)		10.2	3.5%	10.1	2.2%	10.4	3.4%
Amortisation of Intangible Assets (incl. software, etc.)		13.1	-51.7%	28.8	123.0%	36.6	182.7%

- Investment in Property, Plant and Equipment does not include right-of-use asset.

5. Sales of major products

1) Global

Unit: B¥

	FY23					
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
XTANDI	174.1	7.2%	186.9	10.2%	199.0	10.7%
Japan	14.4	2.3%	14.4	7.6%	15.3	3.4%
United States	86.8	3.4%	94.5	3.9%	103.6	9.9%
Established Markets	54.6	16.7%	57.5	14.9%	59.3	11.6%
Greater China	4.4	22.6%	5.7	135.3%	3.4	-11.4%
International Markets	13.8	-1.0%	14.8	15.2%	17.5	26.4%
PADCEV	15.2	44.2%	17.5	71.0%	22.9	86.3%
Japan	2.2	13.1%	2.1	4.4%	2.2	-6.5%
United States	10.5	43.0%	12.5	83.3%	16.0	104.1%
Established Markets	2.4	94.2%	2.7	99.3%	4.2	103.8%
Greater China	-	-	0.0	-	0.2	-
International Markets	0.1	-	0.1	621.6%	0.3	442.2%
XOSPATA	13.0	24.2%	13.3	2.3%	15.0	16.9%
Japan	1.2	6.6%	1.1	4.2%	1.2	-7.1%
United States	7.1	20.2%	6.9	5.4%	7.1	-6.9%
Established Markets	3.3	24.4%	3.9	34.2%	4.0	23.4%
Greater China	0.6	22.9%	0.7	-65.4%	1.7	-
International Markets	0.9	155.3%	0.8	36.4%	1.1	51.2%
VEOZAH	0.6	-	0.7	-	2.3	-
United States	0.6	-	0.7	-	2.3	-
IZERVAY	-	-	1.2	-	4.1	-
United States	-	-	1.2	-	4.1	-
EVRENZO	1.0	31.0%	1.1	34.1%	1.3	42.6%
Japan	0.6	-12.1%	0.5	-10.8%	0.6	-13.9%
Established Markets	0.3	382.8%	0.4	179.2%	0.6	174.4%
International Markets	0.0	-	0.1	169.5%	0.1	437.6%
BETANIS/MYRBETRIQ/BETMIGA	49.2	2.7%	46.6	2.5%	47.0	-1.3%
Japan	7.3	-21.3%	6.8	-16.5%	7.3	-18.3%
United States	26.1	5.6%	22.7	-0.2%	21.6	-6.2%
Established Markets	11.5	14.0%	12.8	19.6%	13.2	14.0%
Greater China	1.0	-3.4%	0.9	-11.5%	1.0	-7.0%
International Markets	3.4	19.3%	3.5	18.0%	4.0	28.6%
PROGRAF	49.1	-5.3%	51.0	5.0%	55.3	7.9%
Japan	8.0	-16.4%	7.3	-17.5%	8.2	-15.0%
United States	2.4	-6.4%	2.6	-0.2%	2.7	-13.1%
Established Markets	17.8	-0.6%	18.1	5.2%	19.2	5.4%
Greater China	12.9	-5.1%	11.6	-2.2%	12.3	4.3%
International Markets	8.0	-2.6%	11.4	41.3%	13.0	51.8%
VESICARE	3.7	-8.4%	3.6	-9.6%	4.1	-4.9%

- FY2022 sales of products in Japan are shown in a gross sales basis. FY2023 sales and forecasts are shown in a net sales basis, as in other regions.

- Established Markets: Europe, Canada, etc.

- Greater China: China, Hong Kong, Taiwan

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Australia, Export sales, etc.

- From FY2023 Q1, the commercial segment of some countries were changed from International Markets to Established Markets. All figures above reflect this change

- PADCEV (United States): Co-promotion revenue from Pfizer

- Astellas' EVRENZO territories: Japan, Europe, the Commonwealth of Independent States, Middle East, South Africa, etc.

2) Revenue by region - FY2022 sales of products in Japan are shown in a gross sales basis. FY2023 sales and forecasts are shown in a net sales basis, as in other regions.

(1) Japan

Unit: B¥

<Global>	FY23					
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
XTANDI	14.4	2.3%	14.4	7.6%	15.3	3.4%
PADCEV	2.2	13.1%	2.1	4.4%	2.2	-6.5%
XOSPATA	1.2	6.6%	1.1	4.2%	1.2	-7.1%
EVRENZO	0.6	-12.1%	0.5	-10.8%	0.6	-13.9%
BETANIS	7.3	-21.3%	6.8	-16.5%	7.3	-18.3%
PROGRAF (Including GRACEPTOR)	8.0	-16.4%	7.3	-17.5%	8.2	-15.0%
HARNAL	0.4	-20.9%	0.3	-28.8%	0.4	-25.4%

<Main products>

SUGLAT [Family]	7.4	-8.3%	7.1	-6.0%	7.5	-8.2%
SUJANU	2.9	-11.1%	2.7	-11.1%	3.0	-8.9%
REPATHA	1.7	1.5%	1.7	6.2%	1.9	8.6%
LINZESS	1.7	-9.1%	1.6	-9.2%	1.8	-6.8%
BLINCYTO	2.4	33.4%	2.6	34.6%	3.3	43.9%
EVENITY	11.5	15.1%	12.0	18.3%	13.2	16.5%
SMYRAF	0.6	0.2%	0.6	-3.7%	0.7	0.1%
Vaccines	0.0	0.9%	3.2	0.8%	1.2	-54.4%
CIMZIA	2.6	-12.7%	2.6	-7.9%	2.6	-13.2%
Total Rx Sales In Japanese market	68.0	2.3%	69.0	5.3%	73.2	3.5%

## (2) United States

Unit: M\$

		FY23					
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Revenue		1,092	-11.9%	1,084	-10.3%	1,185	-3.0%
	XTANDI	632	-2.3%	654	-0.5%	703	5.3%
	PADCEV	76	35.1%	87	76.9%	109	96.4%
	XOSPATA	52	13.6%	48	0.5%	48	-11.5%
	VEOZAH	4	-	5	-	16	-
	IZERVAY	-	-	8	-	28	-
	MYRBETRIQ	190	-0.3%	156	-4.4%	146	-10.5%
	PROGRAF	17	-11.6%	18	-4.3%	18	-17.2%
	AMBISOME	25	-13.9%	26	-7.8%	33	13.5%
	CRESEMBA	62	18.6%	63	17.9%	69	26.1%
	LEXISCAN	29	-84.9%	17	-90.5%	12	-93.1%

## (3) Established Markets

Unit: M€

		FY23					
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Revenue		647	3.3%	651	1.9%	675	0.6%
	XTANDI	365	7.7%	366	1.7%	373	1.1%
	PADCEV	16	79.3%	17	76.7%	27	84.8%
	XOSPATA	22	14.9%	25	19.1%	25	11.8%
	EVRENZO	2	345.9%	3	147.7%	4	147.8%
	BETMIGA	77	5.2%	81	6.1%	83	3.3%
	PROGRAF	119	-8.2%	115	-6.9%	121	-4.4%
	OMNIC	16	-7.8%	17	0.7%	18	-1.2%

- Established Markets: Europe, Canada, etc.

- From FY2023 Q1, the commercial segment of some countries were changed from International Markets to Established Markets. All figures above reflect this change

## (4) Greater China

Unit: B¥

		FY23					
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Revenue		22.5	-2.7%	22.4	2.3%	22.4	11.4%
	XTANDI	4.4	22.6%	5.7	135.3%	3.4	-11.4%
	PADCEV	-	-	0.0	-	0.2	-
	XOSPATA	0.6	22.9%	0.7	-65.4%	1.7	-
	BETMIGA	1.0	-3.4%	0.9	-11.5%	1.0	-7.0%
	PROGRAF	12.9	-5.1%	11.6	-2.2%	12.3	4.3%
	HARNAL	2.0	-15.4%	2.0	-21.2%	2.4	30.1%
	FEBURIC	0.8	0.4%	0.9	-4.6%	1.0	17.8%

- Greater China: China, Hong Kong, Taiwan

## (5) International Markets

Unit: B¥

		FY23					
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Revenue		34.7	2.4%	39.9	17.5%	44.2	21.6%
	XTANDI	13.8	-1.0%	14.8	15.2%	17.5	26.4%
	PADCEV	0.1	-	0.1	621.6%	0.3	442.2%
	XOSPATA	0.9	155.3%	0.8	36.4%	1.1	51.2%
	EVRENZO	0.0	-	0.1	169.5%	0.1	437.6%
	BETMIGA	3.4	19.3%	3.5	18.0%	4.0	28.6%
	PROGRAF	8.0	-2.6%	11.4	41.3%	13.0	51.8%
	HARNAL	4.3	5.0%	4.7	2.5%	4.6	-2.0%

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Australia, Export sales, etc.

- From FY2023 Q1, the commercial segment of some countries were changed from International Markets to Established Markets. All figures above reflect this change



## R&D Pipeline

The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China.

As of Feb 2024

Underlined items indicate changes from the previous announcement in Nov 2023.

### XTANDI and Strategic products (1/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
enzalutamide MDV3100 (XTANDI)	Small molecule	Androgen receptor inhibitor	Metastatic castration-sensitive prostate cancer	China Filed (Sep 2023)	Pfizer	
			Non-metastatic castration-sensitive prostate cancer	US <u>Approved (Nov 2023)</u> Europe Filed (Sep 2023)		
enfortumab vedotin ASG-22ME (PADCEV)	Antibody-drug conjugate (ADC)	Nectin-4 targeted ADC	Metastatic urothelial cancer, platinum-containing chemotherapy and PD-1/L1 inhibitor pretreated	China Filed (Mar 2023)	In-house [Co-development with Pfizer]	
			Metastatic urothelial cancer, previously untreated (first line; combo with pembrolizumab)	US <u>Approved (Dec 2023)</u> Europe Filed (Jan 2024) Japan Filed (Jan 2024)		
			Muscle-invasive bladder cancer (combo with pembrolizumab)	P-III		
			Other solid tumors	P-II		
			Non-muscle-invasive bladder cancer	P-I		
gilteritinib ASP2215 (XOSPATA)	Small molecule	FLT3 inhibitor	Post-chemotherapy maintenance acute myeloid leukemia	P-III	In-house	
			Post-hematopoietic stem cell transplant maintenance acute myeloid leukemia	P-III		
			Newly diagnosed acute myeloid leukemia with high intensity induction of chemotherapy	P-III		
			Newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy	P-I		
			Acute myeloid leukemia in pediatric patients	P-III		

**XTANDI and Strategic products (2/2)**

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
<b>zolbetuximab</b> <b>IMAB362</b>	Antibody	Anti-Claudin 18.2 monoclonal antibody	Gastric and gastroesophageal junction adenocarcinoma	Japan Filed (Jun 2023) US Filed (Jul 2023) Europe Filed (Jul 2023) China Filed (Jul 2023)	In-house (Ganymed)	
			Pancreatic adenocarcinoma	P-II		
<b>fezolinetant</b> <b>ESN364</b> <b>(VEOZAH***)</b>	Small molecule	NK3 receptor antagonist	Vasomotor symptoms due to menopause	Europe <u>Approved (Dec 2023)</u> China P-III Japan <u>P-III</u>	In-house (Ogeda)	
<b>avacincaptad pegol</b> <b>(IZERVAY)</b>	Pegylated RNA aptamer	Complement C5 inhibitor	Geographic atrophy secondary to age-related macular degeneration	Europe Filed (Aug 2023)		
			Stargardt disease	P-II		
<b>resamirigene bilparvovec</b> <b>AT132</b>	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II	In-house (Audentes Therapeutics)	
<b>roxadustat</b> <b>ASP1517/FG-4592</b>	Small molecule	HIF-PH inhibitor	Anemia associated with chronic kidney disease in pediatric patients	Europe P-III	FibroGen	Astellas has rights in Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa.

\* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

\*\* Compounds with "In-house" in this column include ones discovered by collaborative research.

\*\*\* Approved as "VEOZA" in Europe.

**Updates from the previous announcement (Nov 2023):**

**enzalutamide:** Approved in US in Nov 2023 for non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.

**enfortumab vedotin:** Approved in US in Dec 2023 and filed in Europe and Japan in Jan 2024 for locally advanced or metastatic urothelial cancer in the first-line setting.

**fezolinetant:** Approved in Europe in Dec 2023 for moderate to severe vasomotor symptoms associated with menopause. Entered into Phase 3 in Japan for vasomotor symptoms associated with menopause.

**avacincaptad pegol:** Removed the description of the approval in the US in Aug 2023 for geographic atrophy secondary to age-related macular degeneration.

Projects with Focus Area approach (1/2)

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensors **	Remarks
Immuno-oncology	ASP1570	Small molecule	DGK $\zeta$ inhibitor	Cancer	P-I	In-house	
	ASP2138	Antibody	Anti-Claudin 18.2 and anti-CD3 bispecific antibody	Gastric and gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma	P-I	Xencor [Discovered through collaborative research]	
	ASP2074	Antibody	Anti-TSPAN8 and anti-CD3 bispecific antibody	Cancer	P-I	In-house	
	ASP1002	Antibody	Bispecific antibody	Cancer	P-I	In-house	
	ASP1012	Oncolytic virus	Oncolytic virus encoding leptin-IL-2	Cancer	P-I	KaliVir	
Blindness and Regeneration	ASP7317	Cell therapy	Retinal pigment epithelium cells	Geographic atrophy secondary to age-related macular degeneration	P-I	In-house (Ocata Therapeutics)	
Mitochondria	bocidelpar ASP0367/MA-0211	Small molecule	PPAR $\delta$ modulator	Primary mitochondrial myopathies	P-II	In-house (Mitobridge)	
				Duchenne muscular dystrophy	P-I		

**Projects with Focus Area approach (2/2)**

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
Genetic regulation	resamirigene bilparvovec AT132 ***	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II	In-house (Audentes Therapeutics)	
	zocaglusagene nuzaparvovec AT845	Gene therapy (AAV-based gene therapy)	GAA gene replacement to express GAA enzyme	Pompe disease	P-I	In-house (Audentes Therapeutics)	
Targeted Protein Degradation	ASP3082	Small molecule	KRAS G12D degrader	Cancer	P-I	In-house	

\* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

\*\* Compounds with "In-house" in this column include ones discovered by collaborative research.

\*\*\* AT132 is also listed in "XTANDI and Strategic products".

## Others

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
<b>mirabegron</b> <b>YM178</b>	Small molecule	$\beta_3$ receptor agonist	Neurogenic detrusor overactivity in pediatric patients	Europe P-III	In-house	
<b>peficitinib</b> <b>ASP015K</b>	Small molecule	JAK inhibitor	Rheumatoid arthritis	China Filed (Aug 2022)	In-house	
<b>isavuconazole</b>	Small molecule	Azole antifungal	Invasive aspergillosis and invasive mucormycosis in pediatric patients	US <u>Approved (Dec 2023)</u>	Basilea	
<b><u>abiraterone decanote</u></b> <b><u>PRL-02/ASP5541</u></b>	<u>Small molecule</u>	<u>CYP17 lyase inhibitor</u>	<u>Prostate cancer</u>	<u>P-I</u>	<u>In-house</u> <u>(Propella</u> <u>Therapeutics)</u>	

\* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

\*\* Compounds with "In-house" in this column include ones discovered by collaborative research.

### Updates from the previous announcement (Nov 2023):

**isavuconazole:** Approved in US in Dec 2023 for invasive aspergillosis and invasive mucormycosis in pediatric patients.

**abiraterone decanote:** Added a program.

## Rx+ Program

As of Feb 2024

Category	Program	Concept	Status*	Partner	Remarks
Digital health Other services	BlueStar	Digital therapeutics for adults with diabetes	Under clinical trial preparation	Welldoc Roche Diabetes Care Japan	
	Z1608	Digital therapeutic plus remote patient monitoring for heart failure	Under development	Welldoc Eko	
Drug-device combination	pudexacianinium chloride ASP5354	Intraoperative ureter visualization for use in patients undergoing minimally invasive and open abdominopelvic surgeries	P-III	Stryker	

\* The list shows the most advanced stage if the stages are different depending on the region.

### Updates from the previous announcement (Nov 2023):

**pudexacianinium chloride:** Discontinued the development for lymphatic mapping in Phase 2 due to strategic reasons.